Phase II Trial of Capecitabine and Oxaliplatin in Patients with Adeno- and Undifferentiated Carcinoma of Unknown Primary

Katharina Schuette(University Hospital Carl Gustav Carus), G. Huebner(Westpfalz Klinikum), Claus-Henning Koehne(Klinikum Oldenburg), Albrecht Kretzschmar(Roche (Switzerland)), Viktor Gruenwald(Medizinische Hochschule Hannover), Gunnar Folprecht, Michael Stahl(Kliniken Essen-Mitte), Hartmut Link(Medizinische Hochschule Hannover)
Oncology Research and Treatment
January 1, 2009
10.1159/000201125
Cited by 20

Related Papers

Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial
|The Lancet|2019|2.6k
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2014|1.7k
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial
|The Lancet Oncology|2009|960
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial
|The Lancet Oncology|2015|723